Below are the most recent publications written about "Collagen Type II" by people in Profiles.
-
Muirhead KJ, Clause AR, Schlachetzki Z, Dubbs H, Perry DL, Hagelstrom RT, Taft RJ, Vanderver A. Genome sequencing identifies three molecular diagnoses including a mosaic variant in the COL2A1 gene in an individual with Pol III-related leukodystrophy and Feingold syndrome. Cold Spring Harb Mol Case Stud. 2021 12; 7(6).
-
Savarirayan R, Bompadre V, Bober MB, Cho TJ, Goldberg MJ, Hoover-Fong J, Irving M, Kamps SE, Mackenzie WG, Raggio C, Spencer SS, White KK. Best practice guidelines regarding diagnosis and management of patients with type II collagen disorders. Genet Med. 2019 09; 21(9):2070-2080.
-
Bundens G, Buckley A, Milton L, Behling K, Chmielewski S, Cho E, Lozano-Torres X, Selim A, Lackman R, George-Weinstein M, Miller L, D'Angelo M. Measuring clinically relevant endpoints in a serum-free, three-dimensional, primary cell culture system of human osteoarthritic articular chondrocytes. Exp Cell Res. 2017 08 15; 357(2):310-319.
-
Rizzo P, Pitocco D, Zaccardi F, Di Stasio E, Strollo R, Rizzi A, Scavone G, Costantini F, Galli M, Tinelli G, Flex A, Caputo S, Pozzilli P, Landolfi R, Ghirlanda G, Nissim A. Autoantibodies to post-translationally modified type I and II collagen in Charcot neuroarthropathy in subjects with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2017 02; 33(2).
-
Cecen B, Kozaci LD, Yuksel M, Ustun O, Ergur BU, Havitcioglu H. Biocompatibility and biomechanical characteristics of loofah based scaffolds combined with hydroxyapatite, cellulose, poly-l-lactic acid with chondrocyte-like cells. Mater Sci Eng C Mater Biol Appl. 2016 Dec 01; 69:437-46.
-
Biscetti F, Flex A, Pecorini G, Angelini F, Arena V, Stigliano E, Gremese E, Tolusso B, Ferraccioli G. The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. Clin Exp Immunol. 2016 Apr; 184(1):62-72.
-
Brescia AC, Simonds MM, McCahan SM, Fawcett PT, Rose CD. The role of transforming growth factor ? signaling in fibroblast-like synoviocytes from patients with oligoarticular juvenile idiopathic arthritis: dysregulation of transforming growth factor ? signaling, including overexpression of bone morphogenetic protein 4, may lead to a chondrocyte phenotype and may contribute to bony hypertrophy. Arthritis Rheumatol. 2014 May; 66(5):1352-62.
-
Takahashi T, Katsuta S, Tamura Y, Nagase N, Suzuki K, Nomura M, Tomatsu S, Miyamoto K, Kobayashi S. Bone-targeting endogenous secretory receptor for advanced glycation end products rescues rheumatoid arthritis. Mol Med. 2013 Jul 24; 19:183-94.
-
Leckie SK, Bechara BP, Hartman RA, Sowa GA, Woods BI, Coelho JP, Witt WT, Dong QD, Bowman BW, Bell KM, Vo NV, Wang B, Kang JD. Injection of AAV2-BMP2 and AAV2-TIMP1 into the nucleus pulposus slows the course of intervertebral disc degeneration in an in?vivo rabbit model. Spine J. 2012 Jan; 12(1):7-20.
-
Jensen DA, Steplewski A, Gawron K, Fertala A. Persistence of intracellular and extracellular changes after incompletely suppressing expression of the R789C (p.R989C) and R992C (p.R1192C) collagen II mutants. Hum Mutat. 2011 Jul; 32(7):794-805.